NCT05183854View on ClinicalTrials.gov

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

January 7, 2026

Study Completion Date

January 7, 2028

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
BIOLOGICAL

Pneumococcal 20-valent Conjugate Vaccine

Given IM

BIOLOGICAL

Pneumococcal Polyvalent Vaccine

Given IM

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Utah

OTHER